Document is current

Article History

Received: 16 November 2020

Accepted: 21 June 2021

First Online: 25 September 2021

Declarations

:

: This study was approved by the Research Ethics Board committees of the participating Institutions (The Hospital for Sick Children, Beijing Children’s Hospital and Nanfang Hospital). Informed consent or assent was obtained from all parents and/or patients who participated in the original prospective studies conducted in Canada and China.

: Available upon request.

: ASD: Research support by Bayer Healthcare Inc (Research Grant), Novo Nordisk Healthcare Inc (Research Grant), Terry Fox Foundation (Research Grant), Physician’s Services Incorporation (Research Grant). Advisory Committee: International Prophylaxis Study Group (not for profit). OMERACT SIG in MRI in JIA (not for profit), Canadian Committee of Point-of-Care Ultrasound (not for profit). Consultant: Baxter Healthcare Inc, Pfizer Healthcare Inc. PH: Patent on HJHS v2.1 (Hemophilia Joint Health Score) used under license by the Hospital for Sick Children. VB: Chair of the International Prophylaxis Study Group (IPSG), a co-operative study group that is funded by Education grants from Bayer Healthcare, Bioverativ/Sanofi, Novo Nordisk, Pfizer, Shire/Takeda and Spark Therapeutics to the Hospital for Sick Children (“SickKids”) Foundation. Received personal fees from Amgen, Bayer, Novo Nordisk, Pfizer, Roche, Shire/Takeda, Octapharma, and Research support Grants from Novo Nordisk, Bioverativ/Sanofi and Shire/Takeda. RW: Receives research support from Bayer-China. BL: Received honoraria from Takeda China and Bayer China. NZ, AFZ, AM, SY, AZ, JJ, AH, YL, FZ, SS, JS, VB, YP and RM: no competing interests.